ANTIMICROBIAL RESISTANCE: PREVENTION AND MANAGEMENT STRATEGIES From Theory to Bedside: Clinical Reasoning Series Saturday, October 20, 2012 8:30 a.m.–4:30 p.m.

ACCP 2012 Annual Meeting * October 21-24, 2012 * Hollywood, Florida

About From Theory to Bedside: Clinical Reasoning Series
From Theory to Bedside: Clinical Reasoning Series is one component of the professional development program developed by ACCP and approved by the Board of Pharmacy Specialties (BPS) for the recertification of the Board Certified Pharmacotherapy Specialist (BCPS).

This live education series explores cutting-edge, contemporary therapeutic topics, and demonstrates scientifically sound clinical reasoning and decision-making. It provides participants with active learning exercises designed to advance their skills and abilities to critically evaluate scientific evidence and clinical trials and to effectively incorporate into daily practice significant findings that lead to effective and safe patient care.

More information on the BCPS recertification professional development program is available at www.accp.com/careers/boardbcps.aspx.

Activity Overview
“Antimicrobial Resistance: Prevention and Management Strategies” will provide an overview of current and emerging antimicrobial resistance patterns. Expert educators and practitioners will discuss clinical and cost-effective prevention and management strategies for methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), and Clostridium difficile (C. difficile) infections that help inform individual patient care and formulary decisions. Sessions on antimicrobial stewardship and formulary and pharmacoeconomic considerations will further guide the provision of cost-effective services that improve patient outcomes.

Target Audience
Clinical pharmacists and BCPSs seeking recertification credit by continuing education

Continuing Pharmacy Education Credit

The American College of Clinical Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This is an application-based activity; Activity Number: 0217-0000-12-087-L01-P.

To earn continuing pharmacy education credit and to receive your continuing pharmacy education statement of credit for this activity, participants must attend all 6.0 contact hours of programming and complete the associated evaluation at www.accp.com/ce. Partial credit is not available for this activity.

BCPS Recertification Credit
To be eligible for 6.0 CPE hours of recertification credit, BCPSs must attend all 6.0 contact hours of live programming and successfully complete a Web-based posttest by November 30, 2012. Partial credit is not available for this activity.

Learning Objectives

1. Compare and contrast the various mechanisms and emerging patterns of antimicrobial resistance, including MRSA, VRE, and C. difficile.
2. Discuss genomic discoveries relevant to antimicrobial resistance and individualized therapy.
3. Use resistance patterns, susceptibility data, and new clinical evidence to recommend optimal antimicrobial regimens for the management of MRSA, VRE, and C. difficile infections.
4. Design antimicrobial stewardship programs to prevent the emergence of, and/or to eradicate, antimicrobial resistance.
5. Apply clinical and pharmacoeconomic data to individual patient care and formulary decisions.

Agenda

8:30 a.m.	Introduction
8:40 a.m.	Antimicrobial Resistance: Mechanisms and Emerging Patterns
9:40 a.m.	Genomics: Strategies against Resistance Development and Therapeutic Implications
10:00 a.m.	Break
10:15 a.m.	Methicillin-resistant Staphylococcus aureus Infections: Microbiology and Clinical Evidence
11:15 p.m.	Vancomycin-resistant Enterococcus Infections: Microbiology and Clinical Evidence
12:15 p.m.	Lunch
1:45 p.m.	Clostridium difficile Infections: Microbiology and Clinical Evidence
2:30 p.m.	Antimicrobial Stewardship: Lessons Learned and New Opportunities
3:00 p.m.	Break
3:15 p.m.	Formulary and Pharmacoeconomic Considerations
3:45 p.m.	Panel Discussion and Questions
4:15 p.m.	Closing Remarks

Learning objectives for each of the sessions are available at www.accp.com/meetings/am12/.

Program Faculty

	Elizabeth A. Coyle, Pharm.D., FCCM, BCPS Clinical Associate Professor of Infectious Diseases University of Houston College of Pharmacy Adjunct Assistant Professor Department of Infectious Diseases, Infection Control and Employee Health Director of the Infectious Diseases Pharmacy Residency University of Texas M D Anderson Cancer Center Houston, Texas
	Erika J. Ernst, Pharm.D., FCCP, BCPS Associate Professor in the Department of Pharmacy Practice and Science College of Pharmacy University of Iowa Clinical Pharmacy Specialist University of Iowa Hospitals and Clinics Iowa City, Iowa
	Michael B. Kays, Pharm.D., FCCP Associate Professor of Pharmacy Practice Purdue University College of Pharmacy Clinical Specialist in Infectious Diseases at IU Health, Methodist Hospital Adjunct Associate Professor of Medicine Indiana University School of Medicine Indianapolis, Indiana

Program Reviewers
Christopher W. Crank, Pharm.D., BCPS
Associate Director
Clinical Specialist
Clinical Pharmacy Services
Rush University Medical Center
Chicago, Illinois

Richard H. Drew, Pharm.D., M.S., BCPS
Infectious Disease Clinical Pharmacist
Duke University Medical Center
Professor of Pharmacy
Campbell University
Durham, North Carolina

Katie M. Muzevich, Pharm.D.
Clinical Specialist, Critical Care
Clinical Assistant Professor of Pharmacy
VCU Medical Center
Richmond, Virginia

Registration Fee

Registration fee includes syllabus, CPE credit, and access to the BCPS recertification posttest.

Full information on the agenda, learning objectives, faculty, and registration is available at www.accp.com/meetings/am12/.

No commercial support has been received for this activity.